advertisement
Abstract #45645 Published in IGR 13-2
Efficacy and safety of topical travoprost with sofzia(registered trademark) preservative for Japanese glaucoma patients
Kanamoto T; Kiuchi Y; Suehiro T; Nakano T; Nakano Y; Hirota A; Miyata AHiroshima Journal of Medical Sciences 2010; 59: 71-75
The purpose of this study is to evaluate the intraocular pressure (IOP) -lowering effect and safety of topical travoprost with sofzia(registered trademark) and without benzalkonium chloride on Japanese patients with glaucoma. Topical travoprost (0.04%) was used on 39 glaucoma patients with no prior use of topical prostaglandin F2(alpha) analogues (Beginning group). The IOP, number of conjunctival follicules, degrees of conjunctival hyperemia, and degrees of superficial punctate keratitis (SPK, AD-classification) were determined at the beginning of the treatment and after 1 month and 3 months. 37 other patients who were using 0.005% topical latanoprost were switched to 0.04% topical travoprost and analyzed in the same way (Switched group). For the Beginning group, the IOP was significantly decreased after 3 months (p <0.0001). The conjunctival follicule score was decreased significantly (p =0.033). Both the SPK area score and density score for the cases with SPK at the baseline decreased significantly (p =0.034 and p =0.024). In the switched group, the IOP was not changed significantly at 3 months after the switch (p =0.118). Both the conjunctival follicule and hyperemia score were significantly decreased at 3 month (p =0.0074 and p =0.0047). The SPK area score for the cases with SPK at the time of switch decreased significantly (p =0.013). Travoprost with sofzia(registered trademark) preservative had an equal effect in reducing the IOP as latanoprost. It had low toxicity on the ocular surface of Japanese glaucoma patients.
T. Kanamoto. Department of Ophthalmology and Visual Sciences, Graduate School of Biomedical Sciences, Hiroshima University, 1-2-3, Kasumi, Minami-ku, Hiroshima 734-8551, Japan. Email: tkana@hiroshima-u.ac.jp
Classification:
11.16 Vehicles, delivery systems, pharmacokinetics, formulation (Part of: 11 Medical treatment)
11.4 Prostaglandins (Part of: 11 Medical treatment)
